Compounds > u 104067
Page last updated: 2024-11-11

u 104067

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

U 104067: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9888401
CHEMBL ID335071
SCHEMBL ID7990699
MeSH IDM0253233

Synonyms (11)

Synonym
CHEMBL335071
SCHEMBL7990699
u-104067
u 104067
unii-59ij4gv3fc
172035-69-7
9h-pyrimido(4,5-b)indole, 9-(2-(4-morpholinyl)ethyl)-2,4-di-1-pyrrolidinyl-
9-(2-(4-morpholinyl)ethyl)-2,4-di-1-pyrrolidinyl-9h-pyrimido(4,5-b)indole
59IJ4GV3FC ,
u-104067 free base
4-[2-(2,4-dipyrrolidin-1-ylpyrimido[4,5-b]indol-9-yl)ethyl]morpholine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Experiment 2 demonstrated a significant neuroprotective effect of 10 and 30 mg/kg U-104067F using the same dosing schedule."( Two novel pyrrolopyrimidine lipid peroxidation inhibitors U-101033E and U-104067F protect facial motor neurons following neonatal axotomy.
Hall, ED; Oostveen, JA; Smith, SL, 1996)		0.29
" Male Mongolian gerbils were dosed with U-101033E (1."( Neuroprotective effects of the novel brain-penetrating pyrrolopyrimidine antioxidants U-101033E and U-104067F against post-ischemic degeneration of nigrostriatal neurons.
Andrus, PK; Fleck, TJ; Hall, ED; Oostveen, JA, 1997)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID132861The compound was tested for spinal neuroprotection in mouse.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID19550The compound was tested for terminal half-life pharmacokinetic parameter in the male Sprague-Dawley rat.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID185137The compound was tested for inhibition of lung eosinophilia in rat at 10 mg/kg/day, po1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID22411The compound was tested for steady state volume of distribution pharmacokinetic parameter in the male Sprague-Dawley rat.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID133387The compound was tested for inhibition of lung eosinophilia in mouse at 10 mg/kg/day, po1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID20734The compound was tested for tmax value pharmacokinetic parameter in the male Sprague-Dawley rat.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID89974The compound was tested for cytoprotective effect against the human astroglial cells.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID14480The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID14038Oral bioavailability in rat (Sprague-Dawley) (male)1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID185141The compound was tested for inhibition of lung eosinophilia in rat at 3 mg/kg/day, po; Not Tested1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID133389The compound was tested for inhibition of lung eosinophilia in mouse at 30 mg/kg/day, po1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID16282The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID185139The compound was tested for inhibition of lung eosinophilia in rat at 30mg/kg/day, po1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID133388The compound was tested for inhibition of lung eosinophilia in mouse at 3 mg/kg/day, po1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID137600The compound was evaluated for increase in neurological status at 1 hr post head injury using a simple grip test in mouse; Not Determined1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
AID195557The compound was tested for inhibition of [Fe2+]-induced MDA formation in rat brain homogenate; Not Determined1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1,2-dipalmitoylphosphatidylcholine
1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.		1.9910
acrylamide
[no description available]		1.9910acrylamides;
N-acylammonia;
primary carboxamide		alkylating agent;
carcinogenic agent;
Maillard reaction product;
mutagen;
neurotoxin
3-acetylpyridine
3-acetylpyridine: inhibits tremors		1.9910aromatic ketone
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		1.99101,2-diacyl-sn-glycero-3-phosphocholine
cyclic gmp
Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.		1.99103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Anterior Circulation Transient Ischemic Attack
[description not available]		01.9910
Nerve Degeneration
Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.		01.9910
Ischemic Attack, Transient
Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)		01.9910